Apellis: Potential Headache For Alexion

About: Apellis Pharmaceuticals, Inc. (APLS), Includes: ALXN
by: Mehdi Mehdiyev
This article is exclusive for subscribers.
Mehdi Mehdiyev
Long/short equity, Deep Value, value, Growth

The drug which represents a new generation is approaching to final line.

PNH Phase-3 data is likely to be good.

APL-2 has the potential to become a blockbuster in upcoming years.

There is high probability that Apellis Pharmaceuticals becomes buyout target for 2020.

We have witnessed a number of weak results, attempts for "positive" data misinterpretations and manipulations with TAM in this area which generally make it quite hard to determine real clinical benefit and take time to